Cantargia

1 follower

Cantargia utvecklar en antikroppsbaserad behandling riktad mot målmolekylen IL1RAP som har potential att användas för ett flertal olika cancersjukdomar.

Industries

Employees

11-50

Links


Org chart

Collapse
David Liberg
VP, Research
Ton Berkien
Chief Business Officer
Lars Thorsson
VP Clinical Development

Board & advisors

Thoas Fioretos
Founder & Board Member
Anders Martin-Löf
Board Member
Thoas Fioretos
Board Member
Flavia Borellini
Board Member
Magnus Nilsson
Board Member
Damian Marron
Board Member
Damian Marron
Non Executive Director

Teams

This company has no teams yet


Offices